10-Q: Q2 2024 Earnings Report
Express News | Nexalin Technology Announces Closing of $5.2 Million Public Offering
Express News | Nexalin Technology Announces Pricing of $5.2 Million Public Offering
Express News | Nexalin Technology Inc - No Serious Adverse Events Observed in Trial
Express News | Nexalin Technology: Study Shows Strong Statistical Separation Between Patients Receiving Nexalin's Difs Technology With Escitalopram Vs Sham Group
Express News | Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
Express News | Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 Ma Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of Its Gen-3 HALO Clarity Headset Device
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
10-Q: Q1 2024 Earnings Report
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on May 23
Express News | Nexalin Technology Regains Compliance With Nasdaq Continued Listing Requirements
Nexalin Technology Accelerates Manufacturing of Its HALO Clarity Following Successful Usability, Feasibility, and Electrical Testing
Nexalin Technology Awarded Key Patent Related to Its Gen-3 HALO Clarity, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Nexalin Technology Unveils Positive Results of Clinical Study for Gen-2 TACS Device
Nexalin Technology Full Year 2023 Earnings: US$0.63 Loss per Share (Vs US$0.30 Loss in FY 2022)
Nexalin Technology Announces Positive Results of Clinical Study Validating Its Gen-2 TACS Device for Reducing Pain Among Veterans With Mild Traumatic Brain Injury at University of California, San Diego
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology
Nexalin Technology Announces Poster Presentation at "State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment"
No Data
No Data